BioSpace News Archive

Sensorium Therapeutics today announced the appointment of veteran life sciences executive David Southwell to its Board of Directors.

Nuvectis Pharma, Inc. today announced the initiation of a Phase 1a dose escalation clinical trial of NXP900, its novel inhibitor of the SRC/YES1 kinase family (“SFK”).

Corium, LLC announced today the publication of data reinforcing that ADLARITY (donepezil transdermal system) demonstrated favorable skin tolerability and adhesion in a placebo-controlled trial with healthy volunteers.

Pierre Fabre Laboratories , the French pharmaceutical and dermo-cosmetic company, announced the acquisition of Vertical Bio AG, a developer of novel cancer therapies.

Sparta Biomedical Inc., a privately held medical technology company, revolutionizing osteoarthritis treatment, is pleased to announce the close of a heavily oversubscribed convertible funding round.

Curis, Inc. today announced the 2nd Symposium on IRAK4 in Cancer taking place virtually on September 22, 9:00am-1:00pm ET.

ReNAgade Therapeutics today announced the appointment of Laurie Stelzer as Chief Financial Officer.

Sparrow Pharmaceuticals has expanded its PROST! Phase 2 clinical trial (NCT number: NCT05436652 ) of SPI-62 in combination with prednisolone for the treatment of polymyalgia rheumatica (PMR) to include a third cohort.

Ferring Pharmaceuticals announced the first patient in the United States with high-risk Bacillus Calmette-Guérin -unresponsive non-muscle invasive bladder cancer was dosed with the commercially available intravesical gene therapy ADSTILADRIN® as part of the ADSTILADRIN Early Experience Program announced earlier this year.

Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage oncology company, has dosed the first patient with MT-302 in a Phase 1 study for advanced or metastatic epithelial tumors.